Serum YKL-40 levels in patients with ovarian cancer and women with BRCA1 gene mutation--comparison to CA 125 antigen.

Abstract

PURPOSE OF INVESTIGATION:

Our work was undertaken to determine the usefulness ofYKL-40 as a tumor marker in patients with ovarian cancer and women with BRCA 1 gene mutations.

METHODS:

Our study population consisted of 111 patients. They were divided into five study groups: I--newly diagnosed ovarian caner, II--recurrence of ovarian cancer, III--complete remission, IV--benign epithelial tumors and V--patients with BRCA 1 gene mutations. YKL-40 and CA 125 were determined in patient sera.

RESULTS:

YKL-40 in newly diagnosed ovarian cancer patients was significantly higher (181.17 n/ml) than in patients with BRCA 1 gene mutation (97.74 ng/ml, p < 0.01), women with benign epithelial cancer (57.19 ng/ml, p < 0.005) and patients with ovarian cancer at the time of complete remission (58.12 ng/ml, p < 0.005). Taking 124 ng/ml as a cut-off value for YKL-40 (95th percentile for healthly women) we observed higher levels in 50% of patients from group I and in 38% from group II.

CONCLUSIONS:

YKL-40 appears to demonstrate no advantage over CA 125 as a biomarker of ovarian cancer, particularly in women with early-stage tumors. More research is needed on carriers of the BRCA 1 gene muation in view of the elevated YKL-40 concentrations in this group.

• Authors: A Chudecka-Głaz, B Górski, D Zielińska, W Błogowski, I Wojciechowska, R Bedner, I Rzepka-Górska
• Journal: European journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 30 Issue 6 Pg. 668-71 ( 2009) ISSN: 0392-2936 [Print] Singapore
• PMID: 20099501 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Adipokines
• Biomarkers, Tumor
• CA-125 Antigen
• CHI3L1 protein, human
• Chitinase-3-Like Protein 1
• Glycoproteins
• Lectins

Topics

• Adipokines
• Biomarkers, Tumor
• CA-125 Antigen (blood)
• Case-Control Studies
• Chitinase-3-Like Protein 1
• Female
• Genes, BRCA1
• Glycoproteins (blood)
• Humans
• Lectins (blood)
• Mutation
• Ovarian Neoplasms (blood, genetics)